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Background: Abacavir/lamivudine and tenofovir/emtricitabine
fixed-dose combinations are commonly used first-line antiretroviral
therapies, yet few studies have comprehensively compared their
safety profiles.
Methods: Forty-eight–week data are presented from this multicen-
ter, randomized, open-label study comparing the safety profiles of
abacavir/lamivudine and tenofovir/emtricitabine, both administered
with efavirenz, in HLA-B*5701-negative HIV-1–infected adults.
Results: Three hundred eighty-five subjects were enrolled in the
study. The overall rate of withdrawal was high (28%). Changes in
estimated glomerular filtration rate from baseline were similar
between arms [difference 0.953 mLmin211.73 m22 (95% confi-
dence interval: 21.445 to 3.351), P = 0.435]. Urinary excretion of
retinol-binding protein and b-2 microglobulin increased significantly
more in the tenofovir/emtricitabine arm (+50%; +24%) compared
with the abacavir/lamivudine arm (no change; 247%) (P , 0.0001).
A lower proportion achieved viral load ,50 copies per milliliter in
the abacavir/lamivudine arm (114 of 192, 59%) compared with the
tenofovir/emtricitabine arm (137 of 193, 71%) [difference 11.6%
(95% confidence interval: 2.2 to 21.1)]. The overall virological failure
rate was low. The adverse event rate was similar between arms (except
drug hypersensitivity, reported more in the abacavir/lamivudine arm).
Conclusions: The study showed no difference in estimated glome-
rular filtration rate between the arms, however, increases in markers
of tubular dysfunction were observed in the tenofovir/emtricitabine
arm, the long-term consequence of which is unclear. A significant
difference in efficacy favoring tenofovir/emtricitabine was observed.
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INTRODUCTION
Treatment guidelines recommend a range of antiretroviral
therapy (ART) combinations for initial use in treatment-naive,
HIV-1–infected patients.1,2 The fixed-dose combinations of
abacavir sulfate 600 mg/lamivudine 300 mg (Kivexa/Epzicom)
and tenofovir disoproxyl fumarate 300 mg/emtricitabine
200 mg (Truvada) have facilitated once-daily dosing,
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combining 2 nucleoside(tide) reverse transcriptase inhibitors in
1 tablet. Their relative long-term safety profiles are of particular
importance because treatment is currently life long.
Preclinical studies with tenofovir identified renal and
bone toxicities as potential issues with this agent, however, the
incidence of nephrotoxicity in the pivotal clinical studies, which
excluded subjects with low estimated glomerular filtration rate
(eGFR), was relatively low.3,4 Subsequently, case reports have
described serious renal toxicity, including acute renal failure
requiring dialysis, progressive decline in renal function,
proximal renal tubular dysfunction, and Fanconi syndrome.5–7
Further studies have suggested older age, more advanced HIV-1
infection, lower body mass, impaired renal function, and co-
administration of protease inhibitors or additional nephrotoxic
drugs as possible risk factors for tenofovir-associated nephro-
toxicity.6–9 Renal or bone abnormalities have not been identified
in preclinical or clinical studies with abacavir or lamivudine.10
Abacavir is associated with an immunologically mediated
hypersensitivity reaction (HSR) in approximately 5%–8% of
patients during the first 6 weeks of treatment which may be fatal
if abacavir is not discontinued or if it is discontinued and
subsequently reinitiated.11,12 Screening for the major histocom-
patability complex class I allele, HLA*B-5701 and subsequent
avoidance of abacavir use in patients with this allele eliminated
immunologically confirmed HSRs and significantly reduced the
incidence of clinically suspected HSRs.13
Recently abacavir has been reported to be associated with
an increased risk of myocardial infarction (MI)14 and raised
high-sensitive C-reactive protein (hs-CRP) and interleukin-6
(IL-6).15 However, data from different studies are inconsistent,
with the possible association of increasedMI risk being reduced
when traditional risk factors, including renal disease and
intravenous drug use, are taken into account.16–20 In compar-
ative studies with tenofovir/emtricitabine, abacavir/lamivudine
has shown greater increases in total cholesterol (TC), low-
density lipoprotein cholesterol, high-density lipoprotein (HDL)
cholesterol and triglycerides, but the HDL/TC ratio improved in
both arms in ART-naive patients.21 Similarly, lipid levels were
not reduced as much with abacavir/lamivudine compared with
tenofovir/emtricitabine after a switch of therapy.22,23 The data
related to abacavir and MI remain inconclusive.
This study compared the long-term safety profiles of
abacavir/lamivudine with tenofovir/emtricitabine when utilized
with efavirenz. Renal function was assessed by calculation of
eGFR and creatinine clearance, quantification of urinary total
protein and b2-microglobulin (b2M), and in supplemetary
analyses, urinary albumin, retinol-binding protein (RBP), and
N-acetyl-b-D-glucosaminidase (NAG). b2M and RBP are low
molecular weight proteins that are relatively freely filtered by
the glomerulus and almost completely removed from the
ultrafiltrate by the proximal tubules; their increased presence in
the urine usually indicates defective proximal tubular uptake
and/or transport, whereas NAG is a proximal tubule lysosomal
enzyme and its presence in the urine suggests proximal tubular
damage.24 These markers were selected to assess differences in
renal tubular function as significant tubular injury may occur in
the absence of changes in eGFR or marked increases in total
urinary protein excretion.25 In addition, although eGFR is a
fairly sensitive marker of changes in renal function in patients
with eGFR ,60 mL per minute, it performs less well in those
with normal renal function. In addition to renal safety, efficacy,
cardiovascular, and other safety analyses from the primary
48-week timepoint are reported here.
METHODS
Study Design
This multicenter, randomized, open-label study was
conducted in 76 centers across 13 European countries. Eligible
ART-naive, HLA-B*5701-negative, HIV-1–infected adult
subjects were randomized to abacavir/lamivudine or tenofo-
vir/emtricitabine administered with efavirenz for 96 weeks.
Randomization was conducted centrally, stratified by screen-
ing eGFR [calculated by Modified Diet in Renal Disease
(MDRD) equation], black or nonblack race, and body mass
index (BMI). An interactive voice response system with
allocation ratio of 1:1 and block size of 4 was used. Efavirenz
was selected as the third agent because it is recommended by
guidelines and, at the study design stage, was thought to have
no impact on renal or bone endpoints. Subjects unable to
tolerate efavirenz-related central nervous system side effects
were allowed to switch to nevirapine.
Study Population
Eligible subjects were antiretroviral-naive (no previous
therapy with any nonnucleoside reverse transcriptase inhibitor
and #14 days of prior therapy with any other antiretroviral),
HLA-B*5701-negative adults ($18 years of age) with a plasma
HIV-1 RNA $1000 copies per milliliter at screening.
Subjects with an estimated creatinine clearance,50 mL
per minute (Cockcroft-Gault method) during the screening
period were excluded. Similarly, subjects with an active,
AIDS-defining illness at baseline were excluded. Hepatitis B
surface antigen and hepatitic C antibody were assessed at
screening; subjects positive for hepatitis B were excluded. All
subjects were assessed for transmitted resistance to the
antiretrovirals in the study using the Virco TYPE HIV-1
assay. Subjects with evidence of resistance at screening or
prior documented evidence of genotypic and/or phenotypic
resistance were excluded.
Study Procedures
Clinical and laboratory assessments were conducted at
the week 4 and week 12 clinic visits and thereafter at visits
every 12 weeks. Serum, plasma, and urine samples were
collected at each 12-week visit and stored for exploratory
analyses or resistance testing in the event of virologic failure.
A follow-up visit was conducted 2–4 weeks after the
completion of treatment for any subject with an ongoing
adverse event (AE).
Safety Assessments
The primary endpoint for the study was the change from
baseline in eGFR (MDRD), at week 48. Secondary safety
endpoints included change from baseline in eGFR (Cockcroft-
Gault), proportion of subjects with decline from baseline in
eGFR, and proportion of subjects with National Kidney
Foundation chronic kidney disease. b2M was assayed from
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urine samples during the study, whereas albumin, RBP, and
NAG were assayed from stored urine samples. AEs (including
abacavir hypersensitivity) and clinical laboratory evaluations
(including fasting lipid profile) were summarized.
After reports of an association between abacavir and
increased risk of MI,14,15 an exploratory analysis of hs-CRP,
IL-6, and adiponectin was performed on stored serum samples.
Definitions of Renal Toxicities
Subjects who experienced either progression to an eGFR
(MDRD) of ,60 mLmin211.73 m22 or progression to an
eGFR (Cockcroft-Gault) of ,50 mL/min, confirmed at con-
secutive visits, were considered to have a decline in renal
function. Subjects who experienced a confirmed rise in serum
creatinine of $0.5 mg/dL from baseline and serum phosphate
,2.0 mg/dL or one of these 2 elements plus 2 of glycosuria
($250 mg/dL) in a nondiabetic, low serum potassium
(,3 mEq/L) and low serum bicarbonate (,19 mEq/L)
[adapted from Smith et al21] were considered to have proximal
renal tubule dysfunction.
Efficacy Assessments
Secondary efficacy endpoints conducted at weeks 24
and 48 included the proportion of subjects with HIV-1 RNA
,50 copies per milliliter, the proportion of subjects with
HIV-1 RNA ,400 copies per milliliter, absolute values
and change from baseline in HIV-1 RNA and CD4+ cell
count, CD4+ and CD8+ lymphocyte counts, and HIV-1–
associated conditions.
Virologic failure was defined in the protocol as failure
to achieve a 1-log reduction in HIV-1 RNA by week 4, or
a confirmed rebound to $400 copies per milliliter after
confirmed reduction to,400 copies per milliliter by week 24,
or confirmed HIV-1 RNA $400 copies per milliliter after
week 24. In the event of virologic failure, both the baseline and
virologic failure timepoints were assessed using the Virco
TYPE HIV-1 assay for genotypic evaluation.
Statistical Analyses
The primary analysis of interest was conducted at week
48, with a final analysis planned at week 96. For sample size
calculation, a 10 mLmin211.73 m22 difference in change
from baseline in eGFR (MDRD) was considered clinically
relevant. Assuming a SD of 30 mLmin211.73 m22 and a
2-sided 5% level of significance, a total of 380 subjects
(190 per treatment arm) would be needed to provide 90%
power to detect a 10 mL per minute difference between arms.
The intent-to-treat exposed (ITT-E) Population, compris-
ing all randomized subjects who received at least 1 dose of
study medication, was used for assessing primary and
secondary safety objectives and efficacy. The primary analysis
was conducted using a repeated measures mixed model for
change from baseline in MDRD, adjusted for baseline eGFR,
BMI, and race. The impact of age, gender, baseline viral load,
baseline CD4 cell count, concurrent diabetes, hypertension,
hepatitis C or B, country, HIV risk factor, use of prohibited
medication, Centers for Disease Control and Prevention class,
and Framingham cardiovascular risk were assessed for model
inclusion using a stepwise covariate selection method. The
model also included interactions for treatment by visit and
baseline value by visit. Interactions between treatment and other
covariates included in the models were also investigated.
Supportive analyses using Cockcroft-Gault equation and using
a Per Protocol Population were similarly conducted.
The efficacy analyses were based on the proportion who
achieved HIV-1 RNA less than the predefined threshold at
48 weeks (intent-to-treat exposed, using the time to loss of
virologic response algorithm). Responders were subjects with
confirmed viral load less than the threshold, on 2 consecutive
occasions, who had not yet met any nonresponder criterion.
Nonresponders were subjects who never achieved confirmed
HIV-1 RNA less than the threshold, prematurely discontinued
study or study drug for any reason, had confirmed rebound
greater than or equal to the threshold, or had an unconfirmed
HIV-1 RNA greater than or equal to the threshold on their
final study visit.
RESULTS
Study Population
Between July 2007 and December 2007, 392 subjects
were randomized and 385 subjects received treatment with
either abacavir/lamivudine or tenofovir/emtricitabine (Fig. 1).
At the week 48 data cut-off, 107 subjects (28%) had withdrawn
prematurely, 63 subjects (33%) receiving abacavir/lamivudine,
and 44 subjects (23%) receiving tenofovir/emtricitabine.
Baseline demographics were similar across the treatment
arms (Table 1).
Primary Endpoint
At week 48, the adjusted mean change from baseline in
eGFR by MDRD was +0.22 mLmin211.73 m22 and +1.18
mLmin211.73 m22 for the abacavir/lamivudine and tenofovir/
emtricitabine arms, respectively. The adjusted mean difference
between arms was 0.953 mLmin211.73 m22 [95% confidence
interval (CI):21.445 to 3.351, P = 0.435] (Fig. 2). Similarly, no
difference was observed between treatment arms using the
Cockcroft Gault method or the Per Protocol Population.
Baseline eGFR had a significant effect on the change
from baseline in eGFR by both MDRD and Cockcroft-Gault.
Subjects with a baseline eGFR ,90 mL per minute experi-
enced a greater mean change in eGFR (improvement) at week
48 compared with subjects who had a baseline eGFR$90 mL
per minute (P , 0.05). There was no evidence that baseline
BMI or baseline CD4+ cell count had a significant effect on
change from baseline in eGFR.
Secondary Renal Endpoints
No differences were observed between treatment
arms in the proportion of subjects with a decline from
baseline in eGFR of $10 mL per minute, .20 mL per
minute, 10%, or 20% when estimated by either MDRD or
Cockcroft-Gault or the proportion of subjects with renal
failure using the National Kidney Foundation chronic kidney
disease stage categories.
Although no subjects met the protocol-defined decline
in renal function or proximal renal tubule dysfunction criteria,
there were differences between arms for 2 biomarkers of
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tubular renal function, RBP, and b2M (Table 2). A significantly
higher percentage change from baseline in RBP/creatinine
ratio and b2M/creatinine ratio was observed in the tenofovir/
emtricitabine arm (+50%; +24%) compared with the
abacavir/lamivudine arm (no change; 247%) at week 48.
The observed changes in tubular biomarkers occurred within
the first 24 weeks were sustained through to week 48, and the
difference between the 2 treatment arms in the change from
baseline at both week 24 and week 48 was statistically
significant (P , 0.0001).
Secondary Efficacy Endpoints
In the time to loss of virologic response analysis at week
48, a greater proportion of subjects receiving tenofovir/
emtricitabine (148 of 193, 77%) compared with abacavir/
lamivudine (129 of 192, 67%) achieved HIV-1 RNA ,400
TABLE 1. Demographic and Baseline Characteristics (ITT-E Population)
ABC/3TC FDC QD
(n = 192)
TDF/FTC FDC QD
(n = 193)
Total
(n = 385)
Age (years), median (range) 38.0 (19–70) 36.0 (18–66) 37.0 (18–70)
Sex: male, n (%) 159 (83) 154 (80) 313 (81)
Race: black, n (%) 26 (14) 30 (16) 56 (15)
Weight (kg), median (range) 71.0 (46.0–175.0) 73.0 (33.0–107.0) 72.0 (33.0–175.0)
Family history of premature cardiac heart disease, n (%) 23 (12) 18 (9) 41 (11)
Current smoker, n (%) 69 (36) 74 (38) 143 (37)
Current hypertension, n (%) 10 (5) 7 (4) 17 (4)
Hepatitis C reactive, n (%) 16 (8) 18 (9) 34 (9)
Screen eGFR ( mLmin211.73 m22), n (%)
,90 62 (32) 63 (33) 125 (32)
$90 130 (68) 130 (67) 260 (68)
Baseline body mass index (kg/m2), n (%)
,25 127 (66) 130 (67) 257 (67)
$25 64 (33) 63 (33) 127 (33)
Missing 1 (,1) 0 1 (,1)
Baseline CD4+ cell count, median CD4+ (range), cells/mm3 240 (10–610) 230 (10–600) 240 (10–610)
Baseline HIV-1 RNA, median plasma HIV-1 RNA (range), log10copies/mL 5.01 (2.88–6.78) 5.12 (3.31–6.75) 5.06 (2.88–6.78)
CDC category C (AIDS), n (%) 10 (5) 18 (9) 28 (7)
10-year coronary heart disease risk
(using Framingham risk score), median (range)
2.97 (0.00–36.24) 2.90 (0.00–35.28) 2.904 (0.00–36.24)
188* 189* 377
*Total sample size.
ABC/3TC FDC QD abacavir/lamivudine fixed dose combination daily; CDC Centers for Disease Control and Prevention; ITT-E population, intent-to-treat exposed population; TDF/
FTC FDC QD tenofovir/emtricitabine fixed dose combination daily.
FIGURE 1. Summary of subject
disposition.
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copies per milliliter (difference 9.5%, 95% CI: 0.6 to 18.4).
Similarly, a greater proportion of subjects receiving tenofovir/
emtricitabine (137 of 193, 71%) compared with abacavir/lami-
vudine (114 of 192, 59%) achieved HIV-1 RNA ,50 copies
milliliter (difference 11.6%, 95% CI: 2.2 to 21.1). The
difference between the treatment arms was driven by in-
vestigator reported lack of efficacy and early withdrawals
(occurring before virologic suppression), specifically from AEs,
such as abacavir HSR (Fig. 3). Administrative discontinuations
(eg, lost to follow-up, protocol violation, subject decision) in the
study were unusually high and higher in the abacavir/lamivu-
dine arm. Despite HLA B*5701 testing, differences in the rate of
withdrawals due to AEs between the arms was driven by drug
hypersensitivity events (6% in the abacavir/lamivudine arm
versus ,1% in the tenofovir/emtricitabine arm). No difference
between the arms was observed in discontinuation after
suppression, and a high response rate in the observed analysis
indicated that subjects who achieved suppression and remained
in the study continued to respond to treatment.
Treatment response was reduced in subjects with
baseline viral load $100,000 copies per milliliter in both
treatment arms. Differences between arms were observed in
the proportion of subjects achieving viral load,50 copies per
milliliter at week 48 in subjects with baseline viral load
,100,000 copies per milliliter, and $100,000 copies per
milliliter. In the low viral load subgroup, 64% (61 of 95)
versus 75% (62 of 83) of subjects achieved suppression in the
abacavir/lamivudine and tenofovir/emtricitabine arms, respec-
tively. In the high viral load subgroup, corresponding
responses were 55% (53 of 97) versus 68% (75 of 110).
Protocol-defined virologic failures were rare in both
treatment arms. Through week 48, 2% (8 of 385) subjects met
the criteria for virologic failure (6 abacavir/lamivudine, 2
tenofovir/emtricitabine). Two patients, in the abacavir/lamivu-
dine arm, subsequently achieved a viral load ,400 copies per
milliliter although continuing to receive abacavir/lamivudine
and efavirenz. The On Treatment Resistance Population
comprised all subjects who fulfilled the definition of
FIGURE 2. Adjusted mean change
from baseline in eGFR by MDRD
(mLmin211.73 m22) at week
48—repeated measures mixed
model analysis (ITT-E Population).
ITT-E population, intent-to-treat
exposed population.
TABLE 2. Summary of Renal Biomarkers—Week 24 and Week 48
Renal Biomarker
Baseline, Median (IQR)*
Visit
Percentage of Baseline† Ratio of Changes From
Baseline (95% CI) PABC/3TC FDC QD TDF/FTC FDC QD ABC/3TC FDC QD TDF/FTC FDC QD
Albumin (mg/mmol)‡ 0.798 (0.501–1.540) 0.750 (0.477–1.556) Week 24 90% 86% 0.96 (0.78 to 1.17) 0.6650
Week 48 87% 94% 1.08 (0.90 to 1.29) 0.4237
b2M (mg/mmol)‡ 0.013 (0.005–0.024) 0.015 (0.009–0.030) Week 24 72% 124% 1.72 (1.32 to 2.24) ,0.0001
Week 48 53% 124% 2.33 (1.71 to 3.19) ,0.0001
RBP (mg/mmol)‡ 12.26 (8.86–18.57) 12.57 (8.49–16.73) Week 24 108% 151% 1.40 (1.21 to 1.63) ,0.0001
Week 48 100% 150% 1.50 (1.28 to 1.76) ,0.0001
NAG (mmol/h/mmol)‡ 34.39 (21.87–60.99) 34.87 (21.63–47.57) Week 24 85% 92% 1.09 (0.95 to 1.24) 0.2344
Week 48 87% 92% 1.05 (0.91 to 1.22) 0.5084
*Baseline sample size varied for each arm and analyte (n = 146–177) based on collection and availability of stored samples and weeks 24 and 48 sample size further declined
(n = 100–142) due to withdrawals and missing samples.
†Percentage change from baseline in geometric mean, for example, percentages greater than 100 represent an increase from baseline, and less than 100 represent a decrease.
‡Expressed as a ratio with creatinine.
ABC/3TC FDC QD, abacavir/lamivudine fixed-dose combination daily plus efavirenz; TDF/FTC FDC QD, tenofovir/emtricitabine fixed-dose combination daily plus efavirenz.
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protocol-defined virologic failure and had paired baseline and
virologic failure genotypic data for analysis. Three subjects (all
receiving abacavir/lamivudine) developed efavirenz-associated
mutations (K103N, V106M, and G190A/G) and 1 of these
subjects also developed K65R, D67N mutations. Three weeks
before the week 36 virologic failure time point, this subject
started the prohibited medication St Johns Wort, which is
contraindicated with efavirenz; it potentially decreases efavirenz
levels, leading to increased viral load and possible resistance to
efavirenz or cross-resistance to other anti-HIV drugs.
Median CD4+ cell count increases were observed in both
treatment arms through week 48 (abacavir/lamivudine; n = 136,
+150 cells/mm3 and tenofovir/emtricitabine; n = 156, +150
cells/mm3). Eight subjects (abacavir/lamivudine 3 of 192, 2%;
tenofovir/emtricitabine 5 of 193, 3%) experienced HIV-1
disease progression to Centers for Disease Control and
Prevention Class C or death.
Secondary Safety Endpoints
A total of 87% of subjects reported at least 1 AE during
the study with dizziness, nasopharyngitis, and diarrhea being
the most frequent. The proportion of drug-related (in-
vestigator opinion) AEs was similar between the treatment
arms (abacavir/lamivudine 51% (98 of 192); tenofovir/
emtricitabine 47% (91 of 193)]. Drug hypersensitivity,
including abacavir HSR, was more commonly observed in
the abacavir/lamivudine arm [abacavir/lamivudine 6% (12 of
192); tenofovir/emtricitabine ,1% (1 of 193)]. The pro-
portion of drug-related grade 2–4 AEs was numerically
higher in the abacavir/lamivudine arm (29%) than the
tenofovir/emtricitabine arm (20%); dizziness, abnormal
dreams, and drug hypersensitivity were the most common
AEs and occurred in both arms.
Six cases of clinically suspected abacavir HSRs were
reported in this population of HLA-B*5701-negative subjects
(3%). The mean exposure to abacavir/lamivudine was 11.7
days, and all subjects reported a rash. Two subjects reported
fever (1 of whom also reported respiratory and constitutional
symptoms), 2 subjects reported constitutional symptoms,
gastrointestinal or respiratory events, and 2 subjects reported
just rash. All subjects diagnosed with a clinically suspected
HSR fully recovered from the event. There were no reports of
abacavir rechallenge or death in these patients.
A total of nine subjects (abacavir/lamivudine 3%, 5 of
192; tenofovir/emtricitabine 2%, 4 of 193) reported a cardiac
AE by week 48. This included 1 subject in the tenofovir/
emtricitabine arm who experienced a MI and 1 subject in the
abacavir/lamivudine arm who was reported with an in-
tracardiac thrombus. This subject had suffered a MI before
participating in the trial.
Greater increases from baseline were observed in the
abacavir/lamivudine arm compared with the tenofovir/emtri-
citabine arm in median TC (1.36 mg/dL versus 0.66 mg/dL),
triglycerides (0.23 mg/dL versus 0.05 mg/dL), low-density
lipoprotein cholesterol (0.81 mg/dL versus 0.39 mg/dL) and
HDL-cholesterol (0.38 mg/dL versus 0.28 mg/dL). However,
the mean TC/HDL cholesterol ratio reduced in both treatment
arms (20.599 versus 20.934).
In an exploratory analysis of inflammation markers,
minor changes were seen in hs-CRP and IL-6 levels, with no
significant differences observed between the treatment arms.
A rise in adiponectin from baseline to week 48 was observed
in both the abacavir/lamivudine arm (30% increase) and
tenofovir/emtricitabine arm (20% increase); the difference
between the arms was statistically significant (ratio of the
mean ratios = 0.9, (95% CI: 0.9 to 1.0, P = 0.0187).
DISCUSSION
This study evaluated 2 once-daily regimens, abacavir/
lamivudine and tenofovir/emtricitabine, both with efavirenz,
with a particular focus on renal toxicity. Our results confirm
the findings of other trials in a low-risk patient population,
showing that both tenofovir and abacavir have minimal effects
on creatinine-based estimations of renal function.21,26 Data
from randomized and cohort studies suggest that subjects with
FIGURE 3. Proportion of subjects
with HIV-1 RNA ,400 copies per
milliliter and,50 copies per milliliter
by visit—TLOVR analysis. TLOVR,
time to loss of virologic response.
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impaired renal function or proteinuria frequently experience
improvements in eGFR after highly active ART initiation,27,28
and eGFR can remain stable for up to 7 years.29,30 However,
other studies have suggested that HIV-infected patients treated
with ART continue to lose kidney function over time.31
Nonetheless, an overall initial beneficial effect of ART on
kidney function is supported by the SMART study, in which
discontinuation of ARTwas associated with the development
of severe renal events and worsening renal function.32,33
The primary objective of demonstrating a clinically
significant difference in eGFR between treatment arms was
not met, and no patients met decline in renal function or
proximal renal tubular dysfuntion criteria. Of note, an increase of
renal tubular proteinuria was observed in the tenofovir/emtrici-
tabine arm, suggesting altered proximal tubular function. Recent
studies have reported high rates of subclinical proximal
tubulopathy in HIV-1–infected subjects (6%–50% depending
on ART regimen and proximal tubulopathy criteria used) and/or
altered renal phosphate handling, with more severe abnormalities
seen in subjects receiving tenofovir.20,24,34 The risk of tenofovir-
associated tubulopathy has been shown to increase with age and
lower body mass and in the presence of specific polymorphisms
in the genes encoding drug transporters.35 The observed loss of
tubular proteins in this study was milder than seen with Fanconi-
like syndromes,25,36 not associated with serum hypophosphate-
mia, and the long-term clinical significance of low-grade tubular
proteinuria remains unknown. Interestingly, urinary NAG
excretion in our study was similar between the 2 treatment
arms, suggesting that the increased tubular proteinuria in the
tenofovir/emtricitabine arm was more likely the result of altered
tubular function rather than tubular injury.27,37
In this study, a higher proportion of subjects in the
tenofovir/emtricitabine arm achieved undetectable levels of
viremia. Of note, our study was confounded by an unexpectedly
high withdrawal rate in both arms, nearly 30% of the population,
not consistent with other studies.4,21 The majority of these
withdrawals were attributed to early AEs or administrative
reasons. However, more difficult to ascertain is the impact of
conducting this open-label study during a time of increased
concern and uncertainty of the safety and potency of abacavir.14,38
When the study was designed, there was no reason to
suspect that there might be a difference in efficacy between the
2 treatment arms and, as such, efficacy was not the primary
endpoint but was included as a secondary endpoint. Sub-
sequently, 2 additional data sets with a similar nucleoside
backbone randomization, the AIDS Clinical Trials Group
A5202, and Head-to-head Epzicom and Truvada (HEAT)
studies have been reported and results of our study should be
interpreted alongside them.21,38 Both of these studies were
designed with efficacy as the primary endpoint and robustly
powered accordingly. A5202 and HEAT were both double-
blind, placebo-controlled, randomized studies of abacavir/la-
mivudine versus tenofovir/emtricitabine, In A5202, after
a Data and Safety Monitoring Board review, subjects in the
high viral load cohort were unblinded due to a shorter time to
virologic failure in subjects in this subgroup receiving
abacavir/lamivudine. In HEAT, final 96-week results demon-
strated non-inferiority of the 2 arms. Differences in study design,
populations, concomitant antiretrovirals, and success/failure
definitions have been proposed to explain some of the
inconsistencies between study results such as these.39,40
Safety results were broadly consistent with available data
for both regimens. A higher proportion of subjects reported AEs
in the abacavir/lamivudine arm, although examination of
individual AEs did not identify new signals of note. Despite
recruiting only HLA*B-5701-negative subjects to this study, 6
subjects were diagnosed with a clinically suspected abacavir
HSR. An assessment of the symptoms of abacavir HSRs
reported in the PREDICT-1 study indicated that subjects with
immunologically confirmed abacavir HSRs were more likely to
develop symptoms from at least 3 categories of organ and
involving fever.41 Not all of the cases of abacavir HSR reported
in this study had these symptoms.
Recently, data from the D:A:D observational cohort
have raised questions regarding a cardiovascular signal in
subjects receiving abacavir.14 This signal was not apparent
in the present study with a low incidence of cardiac AEs in
both arms; 1 MI was reported in the tenofovir/emtricitabine
arm. Although greater increases in cholesterol levels were seen
in the abacavir/lamivudine arm, the TC:HDL cholesterol ratio,
believed to be the strongest predictor of Coronary Heart
Disease,42 improved similarly in both arms. As exploratory
analyses, stored plasma samples were analyzed for markers of
inflammation.43,44 Our analyses did not provide evidence to
suggest an evolving inflammatory or cardiovascular process in
subjects receiving abacavir or tenofovir.
In summary, no difference in eGFR were observed
between the arms, although increases in markers of tubular
dysfunction were observed in the tenofovir/emtricitabine arm.
The long-term clinical significance of these results are unclear,
and ASSERT continues through to 96 weeks to study this further.
ACKNOWLEDGMENTS
We gratefully acknowledge all subjects who participated
in the study and contributing investigators. This study would
not have been possible without the important contributions of
Alastair Benbow, Catherine Granier, Sara Hughes, David
Leather, Bridin McCaughey, and Daren Thorborn.
REFERENCES
1. European AIDS Clinical Society (EACS). Guidelines for the clinical
management and treatment of HIV infected adults in Europe. Available at:
http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_
HIV_Infected_Adults.pdf. Accessed April 21, 2010.
2. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents.
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults
and Adolescents. Available at: http://aidsinfo.nih.gov/contentfiles/Adult
andAdolescentGL.pdf. Accessed April 21, 2010.
3. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of
tenofovir DF vs stavudine in combination therapy in antiretroviral-naı¨ve
patients: a 3-year randomized trial. JAMA. 2004;292:191–201.
4. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, Emtricitabine and
Efavirenz Vs Zidovudine, Lamivudine and Efavirenz for HIV. N Engl J
Med. 2006;354:251–60.
5. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome
in an AIDS patient on tenofovir treatment—case report and review of
literature. J Infect. 2005;51:E61–E65.
6. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated
acute and chronic kidney disease: a case of multiple drug interactions.
Clin Infect Dis. 2006;42:283–290.
q 2010 Lippincott Williams & Wilkins www.jaids.com | 55
J Acquir Immune Defic Syndr  Volume 55, Number 1, September 1, 2010 Renal Safety of ABC/3TC vs TDF/FTC in HIV-1
7. Campbell LJ, Ibrahim F, Fisher M, et al. Spectrum of chronic kidney
disease in HIV-infected patients. HIV Med. 2009;10:329–336.
8. Post FA, Holt SG. Recent developments in HIVand the kidney. Curr Opin
Infect Dis. 2009;22:43-8.
9. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal
function decline with protease inhibitor-based versus nonnucleoside reverse-
transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102–108.
10. European Medicines Agency. Kivexa Summary of Product Characteristics.
Available at: http://www.ema.europa.eu/humandocs/Humans/EPAR/kivexa/
kivexa.htm. Accessed Accessed April 21, 2010.
11. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions
during therapy with the nucleoside reverse transcriptase inhibitor abacavir.
Clin Ther. 2001;23:1603–1614.
12. Hernandez JE, Cutrell A, Edwatrds M, et al. Clincial risk factors for
hypersensitivitiy reactions to abacavir: retrospective analysis of over 8,000
subjects receiving abacavir in 34 clinical trials [H2013]. Presented at: 43rd
Interscience Conference on Antimicrobial Agents and Chemotherapy;
September 13–17, 2003; Chicago, IL.
13. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hyper-
sensitivity to abacavir. N Engl J Med. 2008;358:568–579.
14. Sabin CA, Worm SW, Weber R, et al. Use of nuceloside reverse transcri-
ptase inhibitors and risk of myocardial infarction in HIV-infected patients
enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;
371:1417–1426.
15. The SMART/INSIGHT and D:A:D Study Groups. Use of nucleoside
reverse transcriptase inhibitors and risk of myocardial infarction in HIV-
infected patients. AIDS. 2008;22:F17–F24.
16. Martı´nez E, Larrousse M, Podzamczer D, et al. Abacavir-based therapy
does not affect biological mechanisms associated with cardiovascular
dysfunction. AIDS. 2010;24:F1–F9.
17. Bedimo R, Westfall A, Drechsler H, et al. Abacavir use and risk of acute
myocardial infarction and cerebrovascular disease in the HAART era
[MOAB202]. Presented at: 5th IAS Conference on HIV Pathogenesis and
Treatment; July 19–22, 2009; Cape Town, South Africa.
18. Constagliola D. The Current Debate on Abacavir; risks and relationship
between viremia and cardiovascular events [MOAB201]. Presented at: 5th
IAS Conference on HIV Pathogenesis and Treatment; July 19–22, 2009;
Cape Town, South Africa.
19. George E, Lucas GM, Nadkarni GN, et al. Kidney function and the risk
of cardiovascular events in HIV-1-infected patients. AIDS. 2010;24:
387–394.
20. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular
abnormalities in the presence of imparied glomerular function in HIV
patients treated with tenofovir. AIDS. 2009;23:689–696.
21. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-
matched, multicenter trial of abacavir/lamivudine and tenofovir/emtrici-
tabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:
1547–1556.
22. Moyle GJ, Sabin CA, Cartledge J, et al. A randomised comparative trial of
tenofovir DF or abacavir as replacement for a thymidine analogue in
persons with lipoatrophy. AIDS. 2006;20:2043–2050.
23. Martinez E, Arranz JA, Podzamczer D, et al. A simplification trial
switching from nucleoside reverse transcriptase inhibitors to once-daily
fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-
infected patients with virolocial suppression. J Acquir Immune Defic
Syndr. 2009;51:290–297.
24. Hall AM, Edwards SG, Lapsley M, et al. Subclinical tubular injury in
HIV-infected individuals on antiretroviral therapy: a cross-sectional
analysis. Am J Kidney Dis. 2009;54:1034–1042.
25. Norden AG, Scheinman SJ, Deschodt-Lanckmann MM, et al. Tubular
proteinuria defined by a study of Dent’s (CLCN5 mutation) and other
tubular diseases. Kidney Int. 2000;57:240–249.
26. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of
a tenofovir disoproxil fumarate vs a thymidine analogue-containing
regimen in antiretroviral-naı¨ve patients. AIDS. 2008;22:2155–2163.
27. Kalayjian RC, Franceschini N, Gupta SK, et al. Suppression of HIV-1
replication by antiretroviral therapy improves renal function in persons
with low CD4 cell counts and chronic kidney disease. AIDS. 2008;22:
481–487.
28. Reid A, Stohr W, Walker AS, et al. Severe renal dysfunction and risk
factors associated with renal impairment in HIV-1 infected adults in Africa
initiating antiretroviral therapy. Clin Infect Dis. 2008;46:1271–1281.
29. Leport C, Bouteloup V, Rossert J, et al. Long-term evolution and deter-
minants of renal function in HIV-infected patients who began receiving
combination antiretroviral therapy in 1997–1999, ANRS CO8 APROCO-
COPILOTE. Clin Infect Dis. 2009;49:1950–1954.
30. Reid A, Stohr W, Walker AS, et al. Glomerular dysfunction and associated
risk factors through four years following initiation of ART in adults with
HIV infection in Africa in the DART trial [TUPEB184]. Presented at: 5th
IAS Conference on HIV Pathogenesis, Treatment and Prevention; July
19–22, 2009; Cape Town, South Africa.
31. Choi AI, Shlipak MG, Hunt PW, et al. HIV-infected persons continue to
lose kidney function despite successful antiretroviral therapy. AIDS. 2009;
23:2143–2149.
32. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided
interruption of antiretroviral treatment. N Eng J Med. 2006;355:
2283–2296.
33. Mocroft A, Wyatt C, Szczech L, et al. Interruption of antiretroviral therapy
is associated with increased plasma cystatin C. AIDS. 2009;23:71–82.
34. Fux C, Opravil M, Cavassini M, et al. Tenofovir and PI use are associated
with an increased prevalence of proximal renal tubular dysfunction in the
Swiss HIV cohort study. Presented at: 16th Conference on Retroviruses
and Opportunistic Infections; February 16–19, 2009; Montreal, Canada.
Abstract 743.
35. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney
tubular dysfunction in HIV-infected patients treated with tenofovir:
a pharmacogenetic study. Clin Infect Dis. 2009;48:e108–e116.
36. Woodward CL, Hall AM, Willimas IG, et al. Tenofovir-associated renal
and bone toxicity. HIV Med. 2009;10:482–487.
37. Norden AG, Gardner SC, Van’t Hoff W, et al. Lysosomal enzymuria
is a feature of hereditary Fanconi syndrome and is related to elevated
CI-mannose-6-P-receptor excretion. Nephrol Dial Transplant. 2008;23:
2795–2803.
38. Sax P, Tierney C, Collier A, et al. Abacavir-lamivudine versus
tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med.
2009;361:2230–2240.
39. Skolnik P. HIV therapy—what do we know, and when do we know it? N
Engl J Med. 2003;349:2351–2352.
40. Ha B, Liao QM, Dix LP, et al. Virologic response and safety of the
abacavir/lamivudine fixed-dose formulation as part of highly active
antiretroviral therapy: analyses of six clinical studies. HIV Clin Trials.
2009;10:65–75.
41. Philips E, Staszewski S, Arribas J, et al. Characteristics of abacavir
hypersensitivity diagnoses according to HLA-B*5701 status and sub-
sequent abacavir patch test result. Presented at: 11th European AIDS
Conference; October 24–27, 2007; Madrid, Spain. Abstract P9.7/04.
42. Preiss D and Sattar N. Lipids, lipid modifying agents and cardiovascular
risk: a review of the evidence. Clin Endocrinol. 2009;70:815–828.
43. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional
biomarkers for prediction of incident cardiovascular events in the
community. JAMA. 2009;302:49–57.
44. Sattar N, Murray HM, Welsh P, et al. Are markers of inflammation more
strongly associated with risk for fatal than for nonfatal vascular events?
PLoS Med. 6(6): e1000099. Doi:10.1371/journal.pmed.1000099.
APPENDIX I: ASSERT INVESTIGATORS
Austria: Richard Greil, L. K. H. Salzburg; Armin Rieger, A. K. H.
Wien; Horst-Michael Schalk, Ordination Schalk; Norbert Vetter, S. M. Z.
Baumgartner Hoehe; Robert Zangerle, Universitaetsklinik Innsbruck. Bel-
gium: Eric Van Wijngaerden, Universitair Ziekenhuis Gasthuisberg; Stefaan
Vandecasteele, Academisch Ziekenhuis St. Jan; Dirk Vogelaers, Universitair
Ziekenhuis Gent. Denmark: Jan Gerstoft, Rigshospitalet; Alex Lund Laursen,
Aarhus Universitetshospital; Lars Mathiesen, Hvidovre Hospital; Henrik
Nielsen, Aalborg Sygehus; Court Pedersen, Odense Universitetshospital.
France: Pierre De Truchis, Hopital Raymond Poincare; Gilles Force, Hopital
Notre Dame du Perpetuel Secours; Marie-Aude Khuong-Josses, Hopital
Delafontaine. Germany: Frank Ackermann, Praxis Dr. Frank Ackermann;
Stefan Esser, Universitaetsklinikum Essen; Eva Jaegel-Guedes, MUC
Research GmbH; Birger Kuhlmann, Gem Praxis Drs. Kuhlmann und Holm;
Hans-Juergen Stellbrink, IPM Study Centre; Matthias Stoll, Medizinische
Hochschule Hannover; Jan van Lunzen, Universitaetsklinikum Eppendorf.
Ireland: Colm Bergin, St. James Hospital; Jack Lambert, Mater Misericordiae
Hospital. Italy: Andrea Antinori, First Nazionale Mal Infettive IRCCS; Pietro
56 | www.jaids.com q 2010 Lippincott Williams & Wilkins
Post et al J Acquir Immune Defic Syndr  Volume 55, Number 1, September 1, 2010
Caramello, Ospedale Amedeo di Savoia; Antonella D’Arminio Monforte,
Azienda Ospedaliera San Paolo; Pietro Di Gregorio, Azienda Ospedaliera
‘‘Cannizzaro’’; Giovanni Di Perri, Ospedale Amedeo di Savoia; Roberto
Esposito, Poloclinico di Modena; Adriano Lazzarin, Fondazione Centro San
Raffaele del Montr Tabor; Patrizia Ortolani, Azienda Unita Sanitaria Locale di
Rimini; Giuliano Rizzardini, Ospedale Luigi Sacco, AO e Polo Universitario;
Stefano Rusconi, Ospedale Luigi Sacco, AO e Polo Universitario; Laura
Sighinolfi, Azienda Ospedaliera Universitaria Arxispedale Sant’Anna; Paolo
Vigano, Ospedale Civile di Lagnano. Latvia: Gunta Sture, Latvijas
Infektologijas Centrs. Netherlands: W Bronsveld, M. C. Alkmaar; I. M.
Hoepelman, U. M. C. Utrecht; J. G. den Hollander, M. C. Rijnmond Zuid 1; H.
G. Sprenger, U. M. C. Groningen; Rob Vriesendorp, M. C. Haaglanden.
Portugal: Teressa Branco, Hospital Fernando da Fonseca 1. Spain: Jose Ramon
Arribas, Hospital la Paz; Boneventura Clotet, Hospital Germans Trias I Pujol;
Pere Domingo, Hospital Santa Creu y Sant Pau; Juan Flores Cid, Hospital
Arnau de Vilanova; Jose M. Gatell, Hospital Clinic de Barcelona; Hernando
Knobel, Hospital del Mar 1; Luis Lopez Cortes, Hospital Virgen del Rocio;
Francisco Orihuela Canadas, Hospital Carlos Haya; Juan Pasquau, Hospital
Virgen de las Nieves; Maria Jesus Perez Elias, Hospital Ramon Y Cajal;
Daniel Podzamczer Palter, Ciudad Sanitaria y Universitaria de Bellvitge;
Federico Pulido, Hospital 12 de Octubre; Rafael Rubio, Hospital 12 de
Octubre. Switzerland: Matthias Cavassini, CHUV Consultation de Medecine
2; Christiane Rosin, University Hospital Basel; HansJakob Furrer, Inselspital
Infektiologie; Josef Jost, Klinik Im Park; Rainer Weber, Universitaetsspital
Zuerich. Unite Kingdom: Jonathan Ainsworth, North Middlesex University
Hospital; Joseph Arumainayagam, Manor Hospital Walsall; David Chadwick,
James Cook University Hospital; Andrew De Burgh-Thomas, Gloucester
Royal Hospital; David Dockrell, Royal Hallamshire Hospital; Martin Fisher,
Brighton and Sussex University Hospitals NHS Trust; Philip Hay, St George’s
Hospital; Margaret Johnson, Royal Free Hospital; Stephen Kegg, Queen
Elizabeth Hospital NHS Trust; Emile Morgan, Royal Bolton Hospital; Graeme
Moyle, Chelsea & Westminster Hospital; Chloe Orkin, Royal London
Hospital, Barts and the London; Jonathan Ross, University Hospital
Lewisham; Edmund Wilkins, North Manchester General Hospital.
q 2010 Lippincott Williams & Wilkins www.jaids.com | 57
J Acquir Immune Defic Syndr  Volume 55, Number 1, September 1, 2010 Renal Safety of ABC/3TC vs TDF/FTC in HIV-1
